Epion Therapeutics, Inc.
Epion Therapeutics is dedicated to developing minimally-invasive treatments for ectatic corneal diseases such as keratoconus. Their innovative EpiSmart approach is designed to provide a transformative, epithelium-on cross-linking system that allows for early intervention, rapid recovery, and improved safety for patients worldwide. The company's mission is to elevate the standard of care in corneal strengthening and preserve vision through advanced research, clinical trials, and innovative medical devices.
Industries
Nr. of Employees
small (1-50)
Epion Therapeutics, Inc.
Products
Minimally‑invasive epithelium‑on corneal cross‑linking system (investigational)
An investigational drug–device combination intended to strengthen the corneal stroma via transepithelial riboflavin delivery and controlled UVA illumination without removing the corneal epithelium.
Minimally‑invasive epithelium‑on corneal cross‑linking system (investigational)
An investigational drug–device combination intended to strengthen the corneal stroma via transepithelial riboflavin delivery and controlled UVA illumination without removing the corneal epithelium.
Services
Clinical development and trial sponsorship for ophthalmic combination products
Sponsorship and operational management of randomized controlled multicenter clinical trials (including Phase 2 and Phase 3) to generate safety and efficacy data for registration.
Preclinical testing and analytical evaluation for ocular drug delivery
Laboratory and independent-laboratory testing to quantify stromal drug loading, compare delivery methods, and support translational development.
Clinical development and trial sponsorship for ophthalmic combination products
Sponsorship and operational management of randomized controlled multicenter clinical trials (including Phase 2 and Phase 3) to generate safety and efficacy data for registration.
Preclinical testing and analytical evaluation for ocular drug delivery
Laboratory and independent-laboratory testing to quantify stromal drug loading, compare delivery methods, and support translational development.
Expertise Areas
- Corneal cross-linking development
- Drug–device combination product development
- Transepithelial ocular drug delivery
- Clinical trial management for ophthalmic interventions
Key Technologies
- Riboflavin‑based photochemical corneal cross-linking
- Transepithelial (epithelium-on) drug delivery
- Topical applicator systems for ocular drug loading
- UVA illumination systems for photochemical therapy